6/5/2023 0 Comments Leica acquire scale bar![]() ![]() UltraPlex fluorescent and chromogenic multiplex IHC technologies are for Research Use Only. “We see the pairing of UltraPlex and BOND automation as a platform for the creation of next generation tissue-based diagnostics for better prediction of therapeutic response and tumor behavior.” “The Cell IDx technology promotes the translation of complex multiplex IHC signatures into manageable three and four biomarker panels that can be automated on Leica Biosystems’ BOND RX platform for high quality, reproducible staining,” he said. Robert Monroe, Chief Medical Officer at Leica Biosystems, agreed with Schwartz on the value of UltraPlex. We are delighted to be a part of this mission.” “Getting this technology into the hands of researchers will advance the science of cancer diagnostics and improve lives. This data on a single tissue section has the potential to inform real time therapy decisions and produce a more focused patient centric approach,” said David Schwartz, co-founder and former CEO of Cell IDx. Multiplex chromogenic IHC allows the pathologist to, for example, detect targets inside and outside the tumor. “The ability to differentiate multiple targets in brightfield has been a long-standing unmet need in clinical pathology. “This acquisition will expand our capabilities in the translational research segment and help researchers to accelerate their journey, transforming scientific exploration into translational outcomes.” “We are thrilled to welcome Cell IDx to the Leica Biosystems team,” said Gustavo Perez-Fernandez, President of Leica Biosystems. During acquisition vibration sensors detect when the stage stands still. 5 positions per second with a 40x objective. In 2021, Leica Biosystems and Cell IDx announced a partnership to combine the benefits of UltraPlex and BOND RX now, Leica Biosystems has acquired Cell IDx, advancing this partnership and adding both scale-up capability and Medical and Scientific Affairs support for Cell IDx customers. A quantum leap in high speed acquisition The high speed linear motor stage offers absolutely precise positioning at previously unattainable speeds, e.g. Together, UltraPlex and BOND RX with high throughput imaging allows researchers to detect three or more markers chromogenically on a single slide using a straightforward pathology workflow. Founded in 2012 and headquartered in San Diego, California, Cell IDx provides multiplex staining panels, tissue staining, and imaging and analysis services.Ĭell IDx’s UltraPlex technology allows simultaneous detection of multiple biomarkers in many immunoassays through fluorescent and chromogenic multiplex immunohistochemistry (“IHC”) staining technology, and automated chromogenic detection of multiple markers on Leica Biosystems’ BOND RX fully automated research stainer. ![]() Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling. Being part of Danaher, Beckman associates will have the opportunity to leverage the power of the Danaher Business System, including the processes by which Danaher accelerates growth through new product innovation and driving sales, marketing and service, as well as its strength in continuously expanding margins.San Diego, CA – November 8, 2022. Beckman provides an excellent complement to our existing Life Sciences & Diagnostics businesses. Lawrence Culp, Jr, said, “Beckman Coulter is an iconic company with a great brand, broad reach and technology leadership well positioned in the markets it serves. IT would become part of Danaher’s Life Sciences & Diagnostics segment, joining Danaher’s Leica, AB Sciex, Radiometer and Molecular Devices businesses. With annual revenues of approximately $3.7 billion, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing with its diagnostic systems found in hospitals and other clinical settings around the world. The transaction, subject to customary conditions is expected to be completed in the first half of 2011. The Beckman Coulter Board of Directors has unanimously recommended that shareholders accept the offer, which represents a premium of approximately 45% to Beckman Coulter’s closing price on December 9, 2010, the date on which market speculation began regarding a potential sale of the Company. Danaher Corporation has entered into a definitive merger agreement to acquire all of the outstanding shares of common stock of Beckman Coulter at a purchase price of $83.50 per share, for a total enterprise value of approximately $6.8 billion, including debt assumed and net of cash acquired. ![]()
0 Comments
Leave a Reply. |